三种临床治疗恶性胸腔积液方案的成本-效果分析

目的:探索不同药物治疗恶性胸腔积液的成本一效果比。方法:96例中量以上的恶性胸腔积液患者(男性62例,女性34例,平均年龄为56·8岁)分为3组,胸液引流后分别予博莱霉素、天地欣、沙培林腔内注射治疗,并运用临床经济学的成本一效果分析进行评价。结果:在3种药物治疗方案中,博莱霉素组有效率为56·25%,1个疗程该药物费用为924·80元,有效率每增加1个百分点,成本为16·44元;天地欣组有效率为66·67%,1个疗程该药物费用为1108·00元,有效率每增加1个百分点,成本为16·62元:沙培林组有效率为76·47%,1个疗程该药物费用为2354·12元,有效率每增加1个百分点,成本为30·78元。结论:不同药物适合不同经济状况的患者。

Cost-effectiveness analysis of three clinic therapeutic schemes for malignant pleural effusions

Objective:TO explore the cost/effectiveness of different drugs in the treatment of malignant pleural effusions. Methods:96 cases of malignant pleural effusions (male 62, female 34, average age 56.8 yrs) were divided into three groups receiving different medication, i.e. group 1 (32 cases)with Bleomycin; group 2 (30 cases)with lentinan; group 3 (34 cases) with Group A Streptococcus. The drugs were infused into cavitas pleuralis respectively after the chest drainage. Date was evaluated using clinic economics cost-effectiveness analysis. Results:Among three groups, the effective rate of Bleomycin was 56.25% and expenditure of one therapeutic course was 924.80 yuans, increase of 1% effective rate was cost 16.44 yuans. The effective rate of lentinan was 66.67% and expenditure of one therapeutic course was 1108.00 yuans, increase of 1% effective rate was costed 16.62 yuans. The effective rate of Group A Streptococcus was 76.47% and expenditure of one therefor ic course was 2354.12 yuans, increase of 1% effective rate was costed 30.78 yuans. Conclusion:Different drugs are fit for patients in the different economic conditions.